NAT2 and breast cancer: In particular, the application of genome-wide analyses (GWAS), beside confirming the involvement of genetic variants linked to detoxification pathways of bladder carcinogens (NAT2, UGT1A, GSTM1), has led to the identification of a number of variants, among which the most accredited are those involved in the telomere’s biology, conferring an increased BC risk [20].